The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani

mBio

Volumn 4, Issue 5, 2013, Pages

  Rostan, Octavie ^a,b   Gangneux, Jean Pierre ^a,c,d   Piquet Pellorce, Claire ^a,b   Manuel, Christelle ^c   McKenzie, Andrew N J ^e   Guiguen, Claude ^c,d   Samson, Michel ^a,b   Robert Gangneux, Florence ^a,c,d  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 12; INTERLEUKIN 33; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT INTERLEUKIN 33; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LEISHMANIA DONOVANI; LIVER BIOPSY; MOUSE; NONHUMAN; PARASITE IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TH1 CELL; TRANSGENIC MOUSE; VISCERAL LEISHMANIASIS; WILD TYPE;

ANIMALS; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKINS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN; TH1 CELLS;

EID: 84887149929     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00383-13     Document Type: Article

References (68)

1. Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP. 2003. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163:69-79.
2. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-490.
3. Mirchandani AS, Salmond RJ, Liew FY. 2012. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol. 33:389-396.
4. Liew FY, Pitman NI, McInnes IB. 2010. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10:103-110.
5. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. 2010. IL-33 and IL-33 receptors in host defense and diseases. Allergol. Int. 59:143-160.
6. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C. 2009. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60:738-749.
7. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska Stolarska M, McKenzie AN, McInnes IB, Liew FY. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U. S. A. 105:10913-10918.
8. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R, Hermoso MA. 2010. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16:1097-1107.
9. Kim YH, Yang TY, Park CS, Ahn SH, Son BK, Kim JH, Lim DH, Jang TY. 2012. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 67:183-190.
10. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y, Niedbala W, McKenzie AN, Teixeira MM, Liew FY, Xu D. 2008. IL-33 induces antigen-specific IL-5 T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181:4780-4790.
11. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY. 2008. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205:339-346.
12. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY. 2010. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 107:650-658.
13. Miller AM, Liew FY. 2011. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease. Pharmacol. Ther. 131:179-186.
14. Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA, Jr, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, Liew FY. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16:708-712.
15. Hazlett LD, McClellan SA, Barrett RP, Huang X, Zhang Y, Wu M, van Rooijen N, Szliter E. 2010. IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 51:1524-1532.
16. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. 2008. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180:2443-2449.
17. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191:1069-1076.
18. Jones LA, Roberts F, Nickdel MB, Brombacher F, McKenzie AN, Henriquez FL, Alexander J, Roberts CW. 2010. IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur. J. Immunol. 40:426-436.
19. Kropf P, Bickle Q, Herath S, Klemenz R, Müller I. 2002. Organ-specific distribution of CD4 T1/ST2 Th2 cells in Leishmania major infection. Eur. J. Immunol. 32:2450-2459.
20. Kropf P, Herath S, Klemenz R, Müller I. 2003. Signaling through the T1/ST2 molecule is not necessary for Th2 differentiation but is important for the regulation of type 1 responses in nonhealing Leishmania major infection. Infect. Immun. 71:1961-1971.
21. Murray HW. 2000. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and-independent regulation. Infect. Immun. 68:6294-6299.
22. Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH, Trinchieri G, Reed SG. 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154: 4623-4629.
23. Donaghy L, Cabillic F, Corlu A, Rostan O, Toutirais O, Guguen Guillouzo C, Guiguen C, Gangneux JP. 2010. Immunostimulatory properties of dendritic cells after Leishmania donovani infection using an in vitro model of liver microenvironment. PLOS Negl. Trop Dis. 4:e703. doi:10.1371/journal.pntd.0000703.
24. Gangneux JP, Donaghy L, Marty P. 2006. Liver involvement during visceral leishmaniasis. Gastroenterol. Clin. Biol. 30:1027-1032. DOI: 10.1016/S0399-8320(06)73378-4. (In French.)
25. Stäger S, Alexander J, Carter KC, Brombacher F, Kaye PM. 2003. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71:4804-4807.
26. Marvie P, Lisbonne M, L'Helgoualc'H A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Théret N, Gascan H, Piquet-Pellorce C, Samson M. 2010. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J. Cell. Mol. Med. 14:1726-1739.
27. Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB. 2011. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J. Intern. Med. 269:29-35.
28. Liew FY. 2012. IL-33: a Janus cytokine. Ann. Rheum. Dis. 71(Suppl 2): i101-i104.
29. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML. 2012. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52:89-99.
30. Palmer G, Gabay C. 2011. Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 7:321-329.
31. Arshad MI, Piquet-Pellorce C, L'Helgoualc'H A, Rauch M, Patrat-Delon S, Ezan F, Lucas-Clerc C, Nabti S, Lehuen A, Cubero FJ, Girard JP, Trautwein C, Samson M. 2012. TRAIL but not FasL and TNFalpha, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 56:2353-2362.
32. Arshad MI, Rauch M, L'Helgoualc'H A, Julia V, Leite-de-Moraes MC, Lucas-Clerc C, Piquet-Pellorce C, Samson M. 2011. NKT cells are required to induce high IL-33 expression in hepatocytes during ConAinduced acute hepatitis. Eur. J. Immunol. 41:2341-2348.
33. Duarte MI, Corbett CE. 1987. Histopathological patterns of the liver involvement in visceral leishmaniasis. Rev. Inst. Med. Trop. Sao Paulo 29:131-136.
34. Kakkar R, Lee RT. 2008. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 7:827-840.
35. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. 2011. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 56:3596-3601.
36. Moussion C, Ortega N, Girard JP. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel'alarmin'? PLoS One 3:e3331. doi:10.1371/ journal.pone.0003331.
37. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner KD, Jr. 1987. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann. Inst. Pasteur Immunol. 138:744-749.
38. Kunes P, Holubcova Z, Kolackova M, Krejsek J. 2010. Interleukin-33, a novel member of the IL-1/IL-18 cytokine family, in cardiology and cardiac surgery. J. Thorac. Cardiovasc. Surg. 58:443-449.
39. Seidelin JB, Rogler G, Nielsen OH. 2011. A role for interleukin-33 in T(H)2-polarized intestinal inflammation? Mucosal Immunol. 4:496-502.
40. Trajkovic V, Sweet MJ, Xu D. 2004. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15:87-95.
41. Carvalho EM, Badaró R, Reed SG, Jones TC, Johnson, WD, Jr. 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76:2066-2069.
42. Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P. 1994. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop. 56:315-325.
43. Mansueto P, Vitale G, Di Lorenzo G, Rini GB, Mansueto S, Cillari E. 2007. Immunopathology of leishmaniasis: an update. Int. J. Immunopathol. Pharmacol. 20:435-445.
44. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N. 2006. Immune responses in kala-azar. Indian J. Med. Res. 123:245-266.
45. Zwingenberger K, Harms G, Pedrosa C, Omena S, Sandkamp B, Neifer S. 1990. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferongamma production. Clin. Immunol. Immunopathol. 57:242-249.
46. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR. 2004. The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201:239-253.
47. Stanley AC, Engwerda CR. 2007. Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85:138-147.
48. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, Johnson WD, Carvalho EM. 1996. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J. Infect. Dis. 173:1515-1518.
49. Hoover DL, Nacy CA, Meltzer MS. 1985. Human monocyte activation for cytotoxicity against intracellular Leishmania donovani amastigotes: induction of microbicidal activity by interferon-gamma. Cell. Immunol. 94:500-511.
50. Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK. 1990. Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J. Clin. Invest. 85:1914-1924.
51. Taylor AP, Murray HW. 1997. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J. Exp. Med. 185:1231-1239.
52. Piehler D, Grahnert A, Eschke M, Richter T, Köhler G, Stenzel W, Alber G. 2013. T1/ST2 promotes T helper 2-cell activation and polyfunctionality in bronchopulmonary mycosis. Mucosal Immunol. 6:405-414.
53. Robert-Gangneux F, Drogoul AS, Rostan O, Piquet-Pellorce C, Cayon J, Lisbonne M, Herbelin A, Gascan H, Guiguen C, Samson M, Gangneux JP. 2012. Invariant NKT cells drive hepatic cytokinic microenvironment favoring efficient granuloma formation and early control of Leishmania donovani infection. PLoS One 7:e33413. doi:10.1371/ journal.pone.0033413.
54. Elshafie AI, Hlin E, Håkansson LD, Elghazali G, Safi SH, Rönnelid J, Venge P. 2011. Activity and turnover of eosinophil and neutrophil granulocytes are altered in visceral leishmaniasis. Int. J. Parasitol. 41:463-469.
55. Mehrotra S, Fakiola M, Oommen J, Jamieson SE, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. 2011. Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east India. BMC Med. Genet. 12:162. doi:10.1186/1471-2350-12-162.
56. Le HT, Tran VG, Kim W, Kim J, Cho HR, Kwon B. 2012. IL-33 priming regulates multiple steps of the neutrophil-mediated anti-Candida albicans response by modulating TLR and dectin-1 signals. J. Immunol. 189: 287-295.
57. Sakai N, Van Sweringen HL, Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ, Lentsch AB. 2012. Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology 56: 1468-1478.
58. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117:1538-1549.
59. Homma Y, Cao S, Shi X, Ma X. 2007. The Th2 transcription factor c-Maf inhibits IL-12p35 gene expression in activated macrophages by targeting NF-kappaB nuclear translocation. J. Interferon Cytokine Res. 27: 799-808.
60. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM. 1995. Regulation of interleukin 12 p40 expression through an NF-kappa B halfsite. Mol. Cell. Biol. 15:5258-5267.
61. Goodbourn S. 1990. The regulation of beta-interferon gene expression. Semin. Cancer Biol. 1:89-95.
62. Ohmori Y, Fukumoto S, Hamilton TA. 1995. Two structurally distinct kappa B sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. J. Immunol. 155:3593-3600.
63. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Kawamoto S, Ishigatsubo Y, Okubo T. 1994. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J. Immunol. 153:2052-2063.
64. Widmer U, Manogue KR, Cerami A, Sherry B. 1993. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1alpha, and MIP-1beta, members of the chemokine superfamily of proinflammatory cytokines. J. Immunol. 150:4996-5012.
65. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ. 2007. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26: 7333-7345.
66. Gregory DJ, Godbout M, Contreras I, Forget G, Olivier M. 2008. A novel form of NF-kappaB is induced by Leishmania infection: involvement in macrophage gene expression. Eur. J. Immunol. 38:1071-1081.
67. Singh VK, Balaraman S, Tewary P, Madhubala R. 2004. Leishmania donovani activates nuclear transcription factor-kappaB in macrophages through reactive oxygen intermediates. Biochem. Biophys. Res. Commun. 322:1086-1095.
68. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM, Nathan CF. 1987. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J. Immunol. 138:2290-2297.